ERIS Lifesciences' Q2 FY 2025-26 Quarterly Results

Result Summary

• ERIS Lifesciences Ltd reported a 2.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 6.6%.
• Its expenses for the quarter were up by 1.2% QoQ and 1.0% YoY.
• The net profit increased 7.5% QoQ and increased 39.6% YoY.
• The earnings per share (EPS) of ERIS Lifesciences Ltd stood at 8.81 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

ERIS Lifesciences Ltd is a pharmaceutical company primarily engaged in the development, manufacturing, and marketing of pharmaceutical products. The company's product portfolio includes formulations in various therapeutic segments, focusing on lifestyle-related disorders. ERIS operates within the healthcare and pharmaceutical industry, which is characterized by innovation-driven growth and is influenced by regulatory environments and healthcare policies. As of the most recent data available, the company has been steadily expanding its market presence and product offerings. Any recent major developments beyond this information are not available in the provided data.

Revenue

In the second quarter of the fiscal year 2026 (Q2FY26), ERIS Lifesciences Ltd reported total income of ₹795.22 crores. This represents an increase of 2.5% from the previous quarter (Q1FY26), where the total income was ₹775.69 crores. Year-over-year (YoY), there was a 6.6% increase compared to the second quarter of the fiscal year 2025 (Q2FY25), which recorded a total income of ₹745.72 crores. These figures indicate a steady upward trend in revenue over both the quarter and the year.

Profitability

The profitability of ERIS Lifesciences Ltd has shown consistent improvement. The profit before tax (PBT) in Q2FY26 was ₹172.39 crores, marking a 7.6% increase from ₹160.21 crores in Q1FY26, and a significant 33.5% rise from ₹129.11 crores in Q2FY25. The tax expense for Q2FY26 was ₹38.20 crores, up 6.1% from the previous quarter and 16.6% from the same quarter last year. The profit after tax (PAT) was ₹134.47 crores in Q2FY26, reflecting a 7.5% increase from Q1FY26, and a notable 39.6% rise from Q2FY25. Earnings per share (EPS) also increased to ₹8.81 in Q2FY26 from ₹8.64 in Q1FY26, and ₹6.72 in Q2FY25, representing a 2.0% QoQ and 31.1% YoY growth.

Operating Metrics

The operating expenses for ERIS Lifesciences Ltd in Q2FY26 amounted to ₹622.83 crores, showing a 1.2% increase from ₹615.48 crores in Q1FY26, and a 1.0% increase from ₹616.61 crores in Q2FY25. These metrics indicate controlled growth in operating expenses relative to revenue growth, which has contributed to the overall improvement in profitability. The consistent increase in total income alongside moderate growth in expenses has positively impacted the company's margins. The financial data provided does not include specific information on other operating metrics such as P/E ratio, debt-to-equity ratio, or current ratio, limiting further analysis in these areas.